Analysis of circulating tumor DNA to monitor metastatic breast cancer.

By S. Dawson, D. Tsui, M. Murtaza, Heather Biggs, O. Rueda, S. Chin, M. Dunning, D. Gale, T. Forshew, B. Mahler-Araujo and 8 more. New England Journal of Medicine, 2013

2,092 citations recorded by the source corpus.

Subfields: Cancer Research, Epidemiology, Oncology

View Paper: https://www.semanticscholar.org/paper/3a1fe8bdcf7e07e0fef71487d520a5b769bb2bbf

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. A. Bardelli
2. Daniel C. Koboldt
3. A. Marusyk
4. K. Polyak
5. Matthew Meyerson
6. Gad Getz
7. J. Reis-Filho
8. L. Diaz

In Epidemiology

1. Razelle Kurzrock

In Oncology

1. A. Marusyk
2. K. Polyak
3. P. Jänne
4. J. Reis-Filho
5. J. Seoane
6. Gad Getz
7. Niko Beerenwinkel
8. Razelle Kurzrock

Citations in the corpus

• RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics (2015, neutral): “…evaluated as liquid biopsies, including plasma DNA (Bettegowda et al., 2014; Chan et al., 2013; Diehl et al., 2008; Murtaza et al., 2013; Newman et al., 2014; Thierry et al., 2014) and circulating tumor cells (Bidard et al., 2014; Dawson et al., 2013; Maheswaran et al., 2008; Rack et al., 2014).”
• The Next-Generation Sequencing Revolution and Its Impact on Genomics (2013, positive): “…for that tumor type (Forshew et al., 2012), or if chromosomal translocations or structural variants already are known from prior characterization of the cancer genome, PCR primers can be designed to amplify the tumorspecific products for NGS and analysis (Dawson et al., 2013; Leary et al., 2012).”
• Integrated digital error suppression for improved detection of circulating tumor DNA (2016, positive): “…29,30 , (2) the detection of emergent, actionable variants associated with resistance during targeted therapy 30-33 , (3) the early measurement of therapeutic responses 6,34 , and (4) the detection of minimal residual disease that is radiographically occult during disease surveillance 6,35-37 .”